Autoimmune Disease Therapeutics to 2016

  • May 2012
  • -
  • Greystone Research Associates

As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically ubiquitous and highly individualized. Until recently, autoimmune disease patients were given little hope for an effective treatment. But the convergence an of improved understanding of autoimmune disease mechanisms and the availability of recombinant cytokines has led to systemic treatments that, while not devoid of side effects, have demonstrated the ability to control autoimmune reactions in a significant number of patients. A number of potentially important pipeline drugs hold the promise of future improvements in outcomes for autoimmune disease patients. This study analyzes current autoimmune therapeutics and assesses the next-generation of candidates and their probable impact on treatment options and the competitive landscape.

Highlights

• Analyzes current therapeutic options for autoimmune diseases, and evaluates emerging therapeutic candidates and assesses their commercial potential
• Assesses existing and evolving immune disease mechanisms and treatment strategies
• Analyzes more than two dozen existing and emerging autoimmune disease targets and target-specific therapeutic drug products
• Evaluates regional and global opportunities for autoimmune therapeutics
• Provides market data and forecasts for six major autoimmune disease segments to 2016

Table Of Contents

Autoimmune Disease Therapeutics to 2016
Executive Summary

Autoimmune Therapeutics Segment Dynamics

Sector Market Dynamics
Patient Demographics and Growth
Chronic Disease and Self-administration
Managed Care and Prescribing Trends
Factors Limiting Growth
Industry Alignment and Competitive Landscape

Autoimmune Therapeutic Market Assessments

Arthritis
Disease Forms and Immune Mechanisms
Therapeutic Strategies
Disease Demographics and Growth
Key Approved Therapies
Development-stage Candidate Assessment
Market Factors
Commercial Outlook and Forecasts

Crohn's Disease
Disease Incidence and Demographics
Current Generation Treatment Options
Therapies in Development
Market Factors
Commercial Outlook and Forecasts

Diabetes
Restoring Islet Cell Function
Therapies in Development
Commercial Outlook and Forecasts

Lupus
The Ongoing Unmet Need
Pipeline Candidates - A Ray of Hope
Market Factors
The Potential for a Lupus-specific Therapy
Commercial Outlook and Forecasts

Multiple Sclerosis
Disease Mechanisms and Therapeutic Strategies
The Market Opportunity
Competitive Landscape
Development-stage Candidate Assessment
Market Factors
Commercial Outlook and Forecasts

Psoriasis
Therapeutic Options and Expanded Indications
Prescribing Trends and Drug Efficacy
Market Sector Factors
Development-stage Candidate Assessment
Commercial Outlook and Forecasts

Market Factors
Risk Factors
Clinical Trial Factors
Product Issues

Autoimmune Therapeutics - Company Profile

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Global Inflammatory Bowel Disease Market 2015-2019

Global Inflammatory Bowel Disease Market 2015-2019

  • $ 3 000
  • Industry report
  • April 2015
  • by Infiniti Research Limited

About Inflammatory Bowel Disease Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn's disease and ulcerative colitis. It causes chronic inflammation of a specific ...

Autoimmune Disease Partnering Terms and Agreements-CP2228-Mar2015

Autoimmune Disease Partnering Terms and Agreements-CP2228-Mar2015

  • $ 2 995
  • Industry report
  • March 2015
  • by Currentpartnering

The Autoimmune Disease Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the ...

Glomerulonephritis Global Clinical Trials Review, H1, 2015

Glomerulonephritis Global Clinical Trials Review, H1, 2015

  • $ 2 500
  • Industry report
  • March 2015
  • by Global Data

Glomerulonephritis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Glomerulonephritis Global Clinical Trials Review, H1, 2015" provides data on the Glomerulonephritis ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.